NCT04622033View on ClinicalTrials.gov

Brodalumab in Palmoplantar Psoriasis

PHASE4UnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

November 30, 2021

Study Completion Date

May 31, 2022

Conditions
Palmoplantar Psoriasis
Interventions
BIOLOGICAL

Brodalumab

brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.

Sponsors
All Listed Sponsors
lead

First OC Dermatology

OTHER